1,217 Shares in Cencora, Inc. (NYSE:COR) Bought by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC acquired a new stake in Cencora, Inc. (NYSE:CORFree Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,217 shares of the company’s stock, valued at approximately $273,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of COR. Concord Wealth Partners acquired a new stake in shares of Cencora in the 3rd quarter valued at approximately $30,000. SYSTM Wealth Solutions LLC bought a new position in Cencora in the 2nd quarter valued at approximately $36,000. Ashton Thomas Securities LLC acquired a new stake in Cencora in the third quarter valued at approximately $41,000. Fairscale Capital LLC bought a new stake in shares of Cencora during the second quarter worth $54,000. Finally, Modus Advisors LLC acquired a new position in shares of Cencora during the fourth quarter worth $54,000. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

COR has been the topic of several recent research reports. Evercore ISI raised their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Finally, Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $275.60.

View Our Latest Analysis on Cencora

Cencora Trading Up 1.2 %

NYSE COR opened at $240.51 on Friday. The stock has a market capitalization of $46.49 billion, a P/E ratio of 32.03, a P/E/G ratio of 1.48 and a beta of 0.49. The business has a 50 day simple moving average of $237.65 and a 200 day simple moving average of $233.72. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a one year low of $214.77 and a one year high of $253.27.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock worth $22,862,734 in the last quarter. Company insiders own 15.80% of the company’s stock.

Cencora Company Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Featured Articles

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.